Sentinel Lymph Node Biopsy in Pure DCIS: Is It Necessary?

Overview

Journal ISRN Surg

Specialty General Surgery

Date 2012 Jun 6

PMID 22666611

Citations 5

Authors

D E Boler

N Cabioglu

U Ince

G Esen

C Uras

Affiliations

Soon will be listed here.

Abstract

Introduction. Sentinel lymph node biopsy (SLNB) in patients with pure ductal carcinoma in situ (DCIS) has been a matter of debate due to very low rate of axillary metastases. We therefore aimed to identify factors in a single institutional series to select patients who may benefit from SLNB. Material and Methods. Patients, diagnosed with pure DCIS (n = 63) between July 2000 and March 2011, were reviewed. All the sentinel lymph nodes were examined by serial sectioning (50 μm) of the entire lymph node and H&E staining, and by cytokeratin immunostaining in suspicious cases. Results. Median age was 51 (range, 30-79). Of 63 patients, 40 cases (63.5%) with pure DCIS underwent SLN, and 2 of them had a positive SLN (5%). In both 2 cases with SLN metastases, only one sentinel lymph node was involved with tumor cells. Patients who underwent SLNB were more likely to have a tumor size >30 mm or DCIS with intermediate and high nuclear grade or a mastectomy in univariate and multivariate analyses. Conclusion. In our series, we found a slightly higher rate of SLNB positivity in patients with pure DCIS than the large series reported elsewhere. This may either be due to the meticulous examination of SLNs by serial sectioning technique or due to our patient selection criteria or both.

Citing Articles

Sentinel lymph node biopsy in patients affected by breast ductal carcinoma in situ with and without microinvasion: Retrospective observational study.

Bertozzi S, Cedolini C, Londero A, Baita B, Giacomuzzi F, Capobianco D Medicine (Baltimore). 2019; 98(1):e13831.

PMID: 30608397 PMC: 6344146. DOI: 10.1097/MD.0000000000013831.

Sentinel lymph node biopsy in clinically detected ductal carcinoma in situ.

Al-Ameer A, Al Nefaie S, Johani B, Anwar I, Al Tweigeri T, Tulbah A World J Clin Oncol. 2016; 7(2):258-64.

PMID: 27081649 PMC: 4826972. DOI: 10.5306/wjco.v7.i2.258.

Intraoperative optical coherence tomography for assessing human lymph nodes for metastatic cancer.

Nolan R, Adie S, Marjanovic M, Chaney E, South F, Monroy G BMC Cancer. 2016; 16:144.

PMID: 26907742 PMC: 4763478. DOI: 10.1186/s12885-016-2194-4.

Intratumoral metabolic heterogeneity predicts invasive components in breast ductal carcinoma in situ.

Yoon H, Kim Y, Kim B Eur Radiol. 2015; 25(12):3648-58.

PMID: 26063655 DOI: 10.1007/s00330-015-3761-9.

DEGRO practical guidelines: radiotherapy of breast cancer II: radiotherapy of non-invasive neoplasia of the breast.

Souchon R, Sautter-Bihl M, Sedlmayer F, Budach W, Dunst J, Feyer P Strahlenther Onkol. 2013; 190(1):8-16.

PMID: 24306068 DOI: 10.1007/s00066-013-0502-3.

References

Darling M, Smith D, Lester S, Kaelin C, Selland D, Denison C . Atypical ductal hyperplasia and ductal carcinoma in situ as revealed by large-core needle breast biopsy: results of surgical excision. AJR Am J Roentgenol. 2000; 175(5):1341-6. DOI: 10.2214/ajr.175.5.1751341. View

Mittendorf E, Arciero C, Gutchell V, Hooke J, Shriver C . Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy. Curr Surg. 2005; 62(2):253-7. DOI: 10.1016/j.cursur.2004.09.011. View

Lee C, Carter D, Philpotts L, Couce M, Horvath L, Lange R . Ductal carcinoma in situ diagnosed with stereotactic core needle biopsy: can invasion be predicted?. Radiology. 2000; 217(2):466-70. DOI: 10.1148/radiology.217.2.r00nv08466. View

Bleiweiss I, Nagi C, Jaffer S . Axillary sentinel lymph nodes can be falsely positive due to iatrogenic displacement and transport of benign epithelial cells in patients with breast carcinoma. J Clin Oncol. 2006; 24(13):2013-8. DOI: 10.1200/JCO.2005.04.7076. View

Yen T, Hunt K, Ross M, Mirza N, Babiera G, Meric-Bernstam F . Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg. 2005; 200(4):516-26. DOI: 10.1016/j.jamcollsurg.2004.11.012. View

Ansari B, Ogston S, Purdie C, Adamson D, Brown D, Thompson A . Meta-analysis of sentinel node biopsy in ductal carcinoma in situ of the breast. Br J Surg. 2008; 95(5):547-54. DOI: 10.1002/bjs.6162. View

Baxter N, Virnig B, Durham S, Tuttle T . Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2004; 96(6):443-8. DOI: 10.1093/jnci/djh069. View

van Deurzen C, Hobbelink M, van Hillegersberg R, van Diest P . Is there an indication for sentinel node biopsy in patients with ductal carcinoma in situ of the breast? A review. Eur J Cancer. 2007; 43(6):993-1001. DOI: 10.1016/j.ejca.2007.01.010. View

Broekhuizen L, Wijsman J, Peterse J, Rutgers E . The incidence and significance of micrometastases in lymph nodes of patients with ductal carcinoma in situ and T1a carcinoma of the breast. Eur J Surg Oncol. 2006; 32(5):502-6. DOI: 10.1016/j.ejso.2006.02.006. View

10.

Dillon M, Quinn C, McDermott E, ODoherty A, OHiggins N, Hill A . Diagnostic accuracy of core biopsy for ductal carcinoma in situ and its implications for surgical practice. J Clin Pathol. 2006; 59(7):740-3. PMC: 1860430. DOI: 10.1136/jcp.2005.034330. View

11.

Polom K, Murawa D, Wasiewicz J, Nowakowski W, Murawa P . The role of sentinel node biopsy in ductal carcinoma in situ of the breast. Eur J Surg Oncol. 2008; 35(1):43-7. DOI: 10.1016/j.ejso.2008.07.007. View

12.

Intra M, Veronesi P, Mazzarol G, Galimberti V, Luini A, Sacchini V . Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Arch Surg. 2003; 138(3):309-13. DOI: 10.1001/archsurg.138.3.309. View

13.

Zavagno G, Carcoforo P, Marconato R, Franchini Z, Scalco G, Burelli P . Role of axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. BMC Cancer. 2005; 5:28. PMC: 555738. DOI: 10.1186/1471-2407-5-28. View

14.

LAGIOS M, Silverstein M . Sentinel node biopsy for patients with DCIS: a dangerous and unwarranted direction. Ann Surg Oncol. 2001; 8(4):275-7. DOI: 10.1007/s10434-001-0275-2. View

15.

Hoorntje L, Schipper M, Peeters P, Bellot F, Storm R, Borel Rinkes I . The finding of invasive cancer after a preoperative diagnosis of ductal carcinoma-in-situ: causes of ductal carcinoma-in-situ underestimates with stereotactic 14-gauge needle biopsy. Ann Surg Oncol. 2003; 10(7):748-53. DOI: 10.1245/aso.2003.11.011. View

16.

Wahedna Y, Evans A, Pinder S, Ellis I, Blamey R, Geraghty J . Mammographic size of ductal carcinoma in situ does not predict the presence of an invasive focus. Eur J Cancer. 2001; 37(4):459-62. DOI: 10.1016/s0959-8049(00)00397-x. View

17.

Wong S, Chao C, Edwards M, Carlson D, Laidley A, Noyes R . Frequency of sentinel lymph node metastases in patients with favorable breast cancer histologic subtypes. Am J Surg. 2002; 184(6):492-8; discussion 498. DOI: 10.1016/s0002-9610(02)01057-7. View

18.

Wilkie C, White L, Dupont E, Cantor A, Cox C . An update of sentinel lymph node mapping in patients with ductal carcinoma in situ. Am J Surg. 2005; 190(4):563-6. DOI: 10.1016/j.amjsurg.2005.06.011. View

19.

Huo L, Sneige N, Hunt K, Albarracin C, Lopez A, Resetkova E . Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ. Cancer. 2006; 107(8):1760-8. DOI: 10.1002/cncr.22216. View

20.

Intra M, Rotmensz N, Veronesi P, Colleoni M, Iodice S, Paganelli G . Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European institute of oncology on 854 patients in 10 years. Ann Surg. 2008; 247(2):315-9. DOI: 10.1097/SLA.0b013e31815b446b. View